"Cell therapy constitutes one of the essential pillars of the medicine of the future, thanks to the discovery of induced reprogrammed cells (iPS) and the consolidation of cell reprogramming."
DR. FELIPE PRÓSPER DIRECTOR. REGENERATIVE MEDICINE RESEARCH PROGRAM
Many tissues have the capacity to regenerate thanks to the presence of stem and/or progenitor cells. In the Regenerative Medicine Program at Cima we study the mechanisms involved in stem cell biology (self-renewal, differentiation, reprogramming and maintenance of pluripotency) as well as their therapeutic application in cardiovascular diseases, osteoarticular diseases, rare metabolic diseases (such as primary hyperoxaluria) or rare muscle diseases (such as Duchenne muscular dystrophy), as well as the application of new products of advanced therapies.
The program consists of clinicians and researchers working especially with cells derived from bone marrow and adipose tissue, induced pluripotency stem cells (iPSCs), cardiac cells obtained by direct reprogramming strategies and by directed differentiation of iPSCs, myogenic precursors, and endothelial cells.
We focus on the collection and characterization of these cells, their functional study and therapeutic use. The use of cell therapies requires a specific regulation, which demands that certain requirements for their manipulation and therapeutic use are met.
Objectives of the Research Program in Regenerative Medicine
To deepen the potential of stem cells
of stem cells
Identify and characterize stem cell populations as well as the mechanisms involved in tissue repair and regeneration processes.
To design new
Validate the application of cell therapy and tissue engineering therapeutic strategies based on endogenous repair mechanisms in experimental models.
Clinical trials of
Establish proof-of-concept studies through clinical trials of advanced therapies.
Development of advanced therapies
Cima works with the Clínica in the development of advanced therapy products under strict quality controls. For the development of these products on a clinical scale, the Clinic has a GMP laboratory, the first accredited laboratory in a hospital within the National Health System.
The GMP laboratory produces advanced cell and tissue therapy drugs under Good Manufacturing Practices (GMP) standards and is authorized by the Spanish Agency of Medicines and Health Products.
Lines of research
PI: Manuel Mazo
We are focused on generating mature human cardiac tissue in the laboratory using tissue engineering strategies, both for therapeutic application and for in vitro modeling of drug effects.
To this end, we aim to gain a better understanding of the factors that determine cardiac maturity, in addition to applying state-of-the-art additive manufacturing strategies. This will be achieved by implementing a highly interdisciplinary strategy, including advanced genomic and gene editing technology in tissue engineering models, fabrication using 3D printing strategies, intelligent materials ("smart materials") and bioreactors among others, together with cardiac phenotypes derived from human iPSCs.
- To build models of diseased and healthy cardiac tissues for use in drug testing as well as precision medicine applications from the use of new fabrication strategies and biomaterials, human iPSC-derived cells and biostimulation (bioreactors).
- Implement advanced genomics tools in the study of cardiac maturation regulation and apply this knowledge to tissue engineering.
- Coordinate the efforts of engineers, chemists, biotechnologists and clinicians to develop a new generation of therapeutic and diagnostic tools.
PI: Xabier Aranguren
We develop new therapeutic alternatives based on the generation of xeno-organs in vivo using stem cells. This will be achieved by microinjecting pluripotent stem cells into genetically modified embryos incapable of generating a certain type of organ/cell type.
The generation of such organs could confer an immune advantage for xenotransplantation into the species of origin of those stem cells.
- To generate "naïve" pluripotent stem cells from different species.
- To produce pre-implanted organ-deficient embryos by Crispr/cas9 technique or by transgenesis.
- To generate rat organs in murine host and primate organs in pigs.
PI: Beatriz Pelacho
We are developing new therapeutic alternatives based on the application of cell and gene therapy, as well as their combination with bioengineering and nanotechnology strategies to prevent and treat adverse cardiac remodeling induced after myocardial ischemia.
Prior knowledge of the molecular mechanisms involved in these processes, together with the reparative action of stem cells, will enable the promotion of different strategies for their clinical application.
- To determine the molecular mechanisms involved in the adverse remodeling that occurs after infarction in order to find new therapeutic targets.
- To demonstrate the efficacy of controlled release systems for proteins/RNA and/or viral vectors for the treatment of cardiovascular diseases.
- Develop tissue engineering strategies based on the combination of collagen membranes and allogeneic stem cells.
PIs: Froilán Granero y Ana Pérez
Due to the increase in life expectancy in advanced societies, diseases of the musculoskeletal system are one of the major causes of disability and chronic pain.
They are highly prevalent in the general population and it is estimated that about a quarter of the European population suffers or has suffered from a disease of this type. In total, more than 100 million European citizens suffer from chronic pain of musculoskeletal origin, and this type of disorder gives rise to the highest recorded proportion of temporary disability of any other type of ailment.
Our aim is not only to develop new therapeutic strategies for musculoskeletal diseases but also to advance our understanding of the basic mechanisms of disease. In general, bone tissue presents a good regenerative capacity that is not exempt from complications, the most serious being the appearance of fracture pseudarthrosis.
The mechanisms that result in the appearance of fracture pseudarthrosis are unknown, so prevention or pharmacological treatment is not possible. On the other hand, the absence of joint tissue regeneration or repair mechanisms means that any damage results in a degenerative process leading to osteoarthritis, characterized by the total loss of joint function. Current pharmacological treatments are palliative and do not halt the progression of the disease, so there is a need to develop therapies that halt the progression of joint degeneration and activate tissue repair mechanisms.
For the treatment of these pathologies, we are interested in the therapeutic potential of mesenchymal progenitor cells (MSCs). Our ultimate goal is to develop effective therapies for the treatment of osteoarticular diseases and their complications, through tissue engineering strategies that combine MSCs, biomaterials and growth factors.
Identification of the molecular mechanisms involved in the natural processes of osteoarticular regeneration.
FROM THE LABORATORY TO THE PATIENT
To deepen the potential of stem cells and propose new drugs and therapeutic strategies that will soon reach the clinic, we work in close collaboration with the Cell Therapy Area of the Clínica Universidad de Navarra and other transversal programs of the Cima.
International project on advanced therapies in regenerative medicine and 3D printing for the treatment of myocardial infarction.
European project, led by the Clínica Universidad de Navarra, to create a biological device to support a diseased heart.
Generation of miniature organs from stem cells to develop new therapeutic alternatives for the treatment of different diseases.
Would you like to help us?
Thanks to the generosity of many people, the Cima Universidad de Navarra is a reality that strives to offer therapeutic solutions to achieve personalized medicine for patients.
Meet the research team
Scientific activity of the
Regenerative Medicine Research Group
Latest scientific publications
- Revealing cell populations catching the early stages of human embryo development in naive pluripotent stem cell cultures Jan 10, 2023 | Magazine: Stem Cell Reports
- Current approaches for the recreation of cardiac ischaemic environment in vitro Jan 6, 2023 | Magazine: International Journal of Pharmaceutics
- In vivo generation of heart and vascular system by blastocyst complementation Oct 4, 2022 | Magazine: bioRxiv
- Sustained inhibition of CC-chemokine receptor-2 via intraarticular deposition of polymeric microplates in post-traumatic osteoarthritis Sep 15, 2022 | Magazine: Drug Delivery and Translational Research